Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050102 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00050102: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00050102 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050102, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine \[DTIC\]) can augment the effects of MDX-010 in patients with chemotherapy naïve metastatic melanoma with a tolerable toxicity profile.
Interventions
- DRUG MDX-010 (CTLA-4)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00050102 record still lists
NCT00050102 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 (CTLA-4) is the first listed.
NCT00050102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050102 about?
NCT00050102 is a clinical study titled "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma". The objectives of this study are to determine the safety and activity profile of multiple doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy (decarbazine \[DTIC\]) can augment the effects of MDX-010 in patients with chemotherapy naïve metastatic melanoma with a tol...
What is the current status of trial NCT00050102?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00050102?
The interventions under investigation include: MDX-010 (CTLA-4) (DRUG).
Who is sponsoring clinical trial NCT00050102?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia